A Phase 1 Study of PF-06840003, an Oral Indoleamine 2,3-dioxygenase 1 (IDO1) Inhibitor in Patients with Recurrent Malignant Glioma
Overview
Authors
Affiliations
Background PF-06840003 is a highly selective indoleamine 2, 3-dioxygenase (IDO1) inhibitor with antitumor effects in preclinical models. This first-in-human phase 1 study evaluated safety, pharmacokinetics/pharmacodynamics, and preliminary efficacy in recurrent malignant glioma to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D). Methods Patients (N = 17) received oral PF-06840003 in four dose-escalation groups: 125 mg once-daily (QD; n = 2); 250 mg QD (n = 4); 250 mg twice-daily (BID; n = 3); 500 mg BID (n = 8). A modified toxicity probability interval method determined the MTD. Results Four patients experienced serious adverse events (SAEs); one with treatment-related SAEs (grade 4 alanine and aspartate aminotransferase elevations). The dose-limiting toxicity (DLT) rate at 500 mg BID was 12.5% (n = 1/8); the MTD was not reached. Following PF-06840003 dosing, median time to maximum plasma concentration for the active enantiomer PF-06840002 was 1.5-3.0 hr and mean elimination half-life was 2 to 4 hr (Cycle 1 Day 1). Urinary recovery of PF-06840002 was low (< 1%). At 500 mg BID, maximum mean percentage inhibition of C10 kynurenine vs endogenous kynurenine was 75% vs 24%. PF-06840002 CSF-to-plasma ratio was 1.00. Disease control occurred in eight patients (47%). Mean duration of stable disease (SD) was 32.1 (12.1-72.3) weeks. Two patients with SD discontinued the study at 450 and 561 days and continued PF-06840003 on compassionate use. Conclusion PF‑06840003 up to 500 mg BID was generally well tolerated with evidence of a pharmacodynamic effect and durable clinical benefit in a subset of patients with recurrent malignant glioma. ClinicalTrials.gov, NCT02764151, registered April 2016.
Snider S, Gagliardi F, De Domenico P, Comai S, Bertazzo A, Nasini S Int J Tryptophan Res. 2025; 18:11786469241312475.
PMID: 39959303 PMC: 11826855. DOI: 10.1177/11786469241312475.
Tan Q, Deng S, Xiong L Int J Mol Sci. 2025; 26(3).
PMID: 39940736 PMC: 11816720. DOI: 10.3390/ijms26030968.
Li H, Liu J, Wang J, Li Z, Yu J, Huang X J Funct Biomater. 2024; 15(12).
PMID: 39728172 PMC: 11676189. DOI: 10.3390/jfb15120372.
Chen X, Xu D, Yu J, Song X, Li X, Cui Y Nutrients. 2024; 16(19).
PMID: 39408347 PMC: 11478743. DOI: 10.3390/nu16193380.
Development of small molecule drugs targeting immune checkpoints.
Chen L, Zhao X, Liu X, Ouyang Y, Xu C, Shi Y Cancer Biol Med. 2024; 21(5).
PMID: 38727005 PMC: 11131045. DOI: 10.20892/j.issn.2095-3941.2024.0034.